These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 32045846)

  • 1. Potential tripeptides against the tyrosine kinase domain of human epidermal growth factor receptor (HER) 2 through computational and kinase assay approaches.
    Seetaha S; Boonyarit B; Tongsima S; Songtawee N; Choowongkomon K
    J Mol Graph Model; 2020 Jun; 97():107564. PubMed ID: 32045846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies.
    Kiriwan D; Seetaha S; Jiwacharoenchai N; Tabtimmai L; Sousa SF; Songtawee N; Choowongkomon K
    Chem Biol Drug Des; 2022 Mar; 99(3):456-469. PubMed ID: 34923743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational analyses of curcuminoid analogs against kinase domain of HER2.
    Yim-im W; Sawatdichaikul O; Semsri S; Horata N; Mokmak W; Tongsima S; Suksamrarn A; Choowongkomon K
    BMC Bioinformatics; 2014 Aug; 15(1):261. PubMed ID: 25089037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hesperetin and Naringenin sensitize HER2 positive cancer cells to death by serving as HER2 Tyrosine Kinase inhibitors.
    Chandrika BB; Steephan M; Kumar TRS; Sabu A; Haridas M
    Life Sci; 2016 Sep; 160():47-56. PubMed ID: 27449398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular dynamics, MM/PBSA and in vitro validation of a novel quinazoline-based EGFR tyrosine kinase inhibitor identified using structure-based in silico screening.
    Ornnork N; Kiriwan D; Lirdprapamongkol K; Choowongkomon K; Svasti J; Eurtivong C
    J Mol Graph Model; 2020 Sep; 99():107639. PubMed ID: 32534372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative anti-proliferative effects of potential HER2 inhibitors on a panel of breast cancer cell lines.
    Zalloum H; AbuThiab T; Hameduh T; AlBayyari S; Zalloum W; Abu-Irmaileh B; Mubarak MS; Zihlif M
    Breast Cancer; 2020 Mar; 27(2):213-224. PubMed ID: 31559601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of In Silico Analysis and In Vitro Assay to Investigate Drug Response to Human Epidermal Growth Factor Receptor 2 Mutations in Lung Cancer.
    Yu X; Wang T; Lou Y; Li Y
    Mol Inform; 2016 Jan; 35(1):25-35. PubMed ID: 27491651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational investigation of
    Yousaf MA; Anwer SA; Basheera S; Sivanandan S
    J Biomol Struct Dyn; 2024; 42(4):1901-1923. PubMed ID: 37154824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.
    Shen X; Chen B; Ma Z; Xie B; Cao X; Yang T; Zhao Y; Qin J; Li J; Cao F; Chen X
    J Recept Signal Transduct Res; 2016; 36(1):89-97. PubMed ID: 26391018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study.
    Yang B; Zhang H; Wang H
    J Mol Model; 2015 Feb; 21(2):24. PubMed ID: 25620423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches.
    Rampogu S; Son M; Baek A; Park C; Rana RM; Zeb A; Parameswaran S; Lee KW
    Comput Biol Chem; 2018 Jun; 74():327-338. PubMed ID: 29702367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression, purification, and characterization of the native intracellular domain of human epidermal growth factor receptors 1 and 2 in Escherichia coli.
    Seetaha S; Ratanabanyong S; Choowongkomon K
    Appl Microbiol Biotechnol; 2019 Oct; 103(20):8427-8438. PubMed ID: 31506720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies.
    Aiebchun T; Mahalapbutr P; Auepattanapong A; Khaikate O; Seetaha S; Tabtimmai L; Kuhakarn C; Choowongkomon K; Rungrotmongkol T
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33921332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
    Meng X; Li Y; Tang H; Mao W; Yang H; Wang X; Ding X; Xie S
    Amino Acids; 2016 Feb; 48(2):487-97. PubMed ID: 26439378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of pyrazolyl-nitroimidazole derivatives as potential EGFR/HER-2 kinase inhibitors.
    Tao XX; Duan YT; Chen LW; Tang DJ; Yang MR; Wang PF; Xu C; Zhu HL
    Bioorg Med Chem Lett; 2016 Jan; 26(2):677-683. PubMed ID: 26652482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural Products as Chemopreventive Agents by Potential Inhibition of the Kinase Domain in ErbB Receptors.
    Olivero-Acosta M; Maldonado-Rojas W; Olivero-Verbel J
    Molecules; 2017 Feb; 22(2):. PubMed ID: 28218686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioiodinated Small-Molecule Tyrosine Kinase Inhibitor for HER2-Selective SPECT Imaging.
    Tang L; Peng C; Tang B; Li Z; Wang X; Li J; Gao F; Huang L; Xu D; Zhang P; Zhuang R; Su X; Chen X; Zhang X
    J Nucl Med; 2018 Sep; 59(9):1386-1391. PubMed ID: 29653973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric regulation of epidermal growth factor (EGF) receptor ligand binding by tyrosine kinase inhibitors.
    Macdonald-Obermann JL; Pike LJ
    J Biol Chem; 2018 Aug; 293(35):13401-13414. PubMed ID: 29997256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.